Skip to main content
Figure 1 | Vascular Cell

Figure 1

From: Arteriogenic therapy based on simultaneous delivery of VEGF-A and FGF4 genes improves the recovery from acute limb ischemia

Figure 1

AAV-transduced HEK-293 cells are viable and efficiently produce the protein products of the introduced transgenes. (A) Representative pictures of β-galactosidase in situ staining of HEK-293 cells transduced with different doses of AAV-LacZ vector (100, 1000 and 10 000 MOI). Magnification 400x. (B) LDH-based cytotoxicity assay in conditioned media 72 h after transduction. (C) Expression cassettes of AAV vectors used in the study. (D) Results of ELISA determining human VEGF-A in the cell culture media. (E) Results of ELISA determining human FGF4 release into the cell culture media. Control stands for non-transduced cells. Representative data out of two independent experiments performed in duplicates. Values are means ± SD; *p < 0.05 vs control and AAV-LacZ.

Back to article page

Vascular Cell

ISSN: 2045-824X

Contact us